Technology Bundle ID: TAB-2740

Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity

Request More Info
Licensing Contact:
Primary Inventors: 
Edwin Ades (CDC)
Danny Jue (CDC), George Carlone (CDC), Jacquelyn Sampson (CDC), Scott Johnson (CDC)
Development Stage: 
Pre-clinical (in vivo)
Development Status: 
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 

Disease caused by Streptococcus pneumoniae (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of antigenic epitopes of the PsaA (37-kDa) protein from S. pneumoniae. In addition, the peptides of the invention have the capability of serving as specific immunogens in a subject, effectively eliciting the production of antibodies and conferring protective immunity against S. pneumoniae infection following immunognen administration.

  • Development or improvement of S. pneumoniae vaccines
  • Public health vaccination programs
  • Clinical serodiagnostic development
  • May provide better immune protection than current, single-epitope based vaccines
  • Broader spectrum of S. pneumoniae serotypes addressed
  • Immunization with these peptides was shown to reduce carriage in murine studies


PCT Application PCT/US2001/021626
Filed on 2001-07-10
US Pat 6,903,184

Issued 2005-06-07
US Pat 7,501,132

Issued 2009-03-10
US Pat 8,642,048

Issued 2014-02-04

Various international patent applications pending or issued


Jan 27, 2014

Data Source: